BioCryst Pharmaceuticals, Inc. (BCRX)
Market Cap | 867.89M |
Revenue (ttm) | 331.41M |
Net Income (ttm) | -226.54M |
Shares Out | 206.15M |
EPS (ttm) | -1.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,808,518 |
Open | 4.370 |
Previous Close | 4.380 |
Day's Range | 4.180 - 4.420 |
52-Week Range | 4.180 - 9.070 |
Beta | 1.93 |
Analysts | Strong Buy |
Price Target | 13.83 (+228.5%) |
Earnings Date | May 6, 2024 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships w... [Read more]
Financial Performance
In 2023, BCRX's revenue was $331.41 million, an increase of 22.37% compared to the previous year's $270.83 million. Losses were -$226.54 million, -8.33% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price forecast is $13.83, which is an increase of 228.50% from the latest price.
News
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on ...
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted ...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmun...
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) —
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat...
BioCryst Launches ORLADEYO® (berotralstat) in Italy
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), ha...
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on ...
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of re...
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales...
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Co...
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment with ORLADEYO – – Results published in JACI: In Prac...
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANM...
BioCryst Launches ORLADEYO® (berotralstat) in Spain
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted m...
BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)
– Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across 12-month period – – Additional analysis from APe...
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates from its drug discovery process and additional therapies from its...
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®
– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO reven...
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® ...
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial e...
BioCryst to Host R&D Day on November 3
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November ...
BioCryst to Report Third Quarter 2023 Financial Results on November 2
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on ...
INESSS Recommends Public Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INE...
Harley, Spotify, and 8 Other Dead Money Stocks That Are Poised to Come Alive
Barron's looked at stocks in the Russell 3000 that have done little for the past five years and identified 10 stocks where improving analyst sentiment could signal better days ahead.
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS...